Applied Chemistry for Engineering (공업화학)

The Korean Society of Industrial and Engineering Chemistry (한국공업화학회)
권호 표지

Preparation and Characterizatino of Nano-sized Liposome Containing Proteins Derived from Coptidis rhizoma

황련유래 단백질이 함유된 나노리포좀의 제조 및 특성

  • Received : 2005.09.09
  • Accepted : 2005.12.12
  • Published : 2006.02.10
Download PDF
⟨ Previous Next ⟩

Abstract

Coptidis Rhizoma, an antimicrobial agent from natural source, is known to have the antiviral effect on the Candida albicans that causes the infectious dermatitis. The valuable protein was extracted from the Coptidis Rhizoma, To prevent denaturalization from external stimulus and improve adsorption onto the skin, the nano-sized liposomes were prepared as a carrier. The CPR-containing liposomes showed an average diameter of 187 nm, surface charge of 3.337 mV and 33% encapsulation efficiency. The release behavior of CRP from the liposome was investigated with various temperature and releasing time. The PVA solution was coated on the surface of liposome to improve the stability. The coated liposome showed slow release behavior in comparison with the non-coated liposome. The CRP in the liposome maintained the effect on the Candida albicans after treating it at 50 and with ultraviolet for 24 h.

천연 항진균 물질인 황련(Coptidis Rhizoma)은 감염성 피부염을 유발시키는 주 원인균인 Cadida albicans에 항세균 작용이 있다고 알려져 있다. 본 연구에서는 황련유래 단백질(Proteins derived from Coptidis Rhizoma, CRP)의 유효 성분을 추출하여 안정성 도모 및 피부 세포 내에 안정하게 흡수시키는 물질 전달체로서 리포좀을 제조하였다. 황련유래 단백질을 함유한 리포좀 입자의 평균 크기는 187 nm, 표면전하는 3.337 mV이며 포집효율은 33%이었다. 온도, 저장시간에 따른 CRP의 방출 거동을 확인하였으며, 리포좀의 안정성을 증가시키기 위하여 리포좀을 poly(vinyl alcohol) (PVA)로 코팅하였다. 코팅된 리포좀은 코팅 안된 리포좀에 비하여 낮은 방출율을 나타내었다. 또한, 리포좀에 함유된 CRP의 항캔디다 효과는 $50^{\circ}C$ 또는 자외선(UV)으로 24 h 처리한 후에도 지속됨을 확인하였다.

Keywords

Acknowledgement

Supported by : 산업자원부

References

  1. M. Weinberger, L. Leibovici, S. Perez, Z. Samra, I. Ostfeld, I. Levi, E. Bash, D. Turner, A. Goldschmied-Reouven, G. Regev-Yochay, S. D. Pitlik, and N. Keller, J. Hosp. Infec., in press
  2. M. Viejo-Diaz, M. T. Andres, and J. F. Fierro, FEMS Immunology and Medi. Microbiology, 42, 181 (2004) https://doi.org/10.1016/j.femsim.2004.04.005
  3. I. Mohammedi, A. Thiebaut, M. A. Piens, L. Argaud, O. Martin, and D. Robert, J. Infec., 1 (2004)
  4. S. G. Franzblau and C. Cross, J. Ethnopharmacology, 15, 279 (1986) https://doi.org/10.1016/0378-8741(86)90166-2
  5. N. Miura, M. Yamamoto, T. Ueki, T. Kitani, K. Fukuda, and Y. Komatsu, Biochem. Phamacology, 53, 1315 (1997) https://doi.org/10.1016/S0006-2952(97)87955-5
  6. M. L. Freile, F. Giannini, G. Pucci, A. sturniolo, L. Rodero, O. Pucci, V. Balzareti, and R. C. Enriz, Fitoterapia, 74, 702, (2003) https://doi.org/10.1016/S0367-326X(03)00156-4
  7. H. K. Kim, J. H. Lee, J. K. Shim, and Y. M. Han, J. Pharm. Soc. Korea, 49, 323, (2005)
  8. S. S. Feng and G. F. Huang, J. Control. Rel., 71, 53 (2001) https://doi.org/10.1016/S0168-3659(00)00364-3
  9. B. S. Jin, Y. M. Han, K. H. Lee, and M. J. Choi, J. Korean Ind. Eng. Chem., 15, 205 (2004)
  10. S. S. Feng, G. Ruan, and Q. T. Li, Biomaterials, 25, 5181 (2004) https://doi.org/10.1016/j.biomaterials.2003.12.013
  11. E. Touitou, N. Dayan, L. Bergelson, B. Godin, and M. Eliaz, J. Control. Rel., 65, 403 (2000) https://doi.org/10.1016/S0168-3659(99)00222-9
  12. B. Godin and E. Touitou, J. Control. Rel., 94, 365 (2004) https://doi.org/10.1016/j.jconrel.2003.10.014
  13. B. W. Barry, Eur. J. Pharm. Sci., 14, 101 (2001) https://doi.org/10.1016/S0928-0987(01)00167-1
  14. J. A. Bouwstra and P. L. Honeywell-Nguyen, Adv. Drug Deliv. Rev., 54, S41 (2002) https://doi.org/10.1016/S0169-409X(02)00114-X
  15. K. Iga, Y. Ogawa, and H. Toguchi, Pharm. Res., 9, 658 (1992) https://doi.org/10.1023/A:1015858228394
  16. A. Ono, M. Yamaguchi, I. Horikoshi, T. Shintani, and M. Ueno, Biol. Pharm. Bull., 17, 166 (1994) https://doi.org/10.1248/bpb.17.166
  17. K. Kono, H. Hayashi, and T. Takagishi, J. Control. Rel., 30, 69 (1994) https://doi.org/10.1016/0168-3659(94)90045-0
  18. K. Kono, A. Henmi, H. Yamashita, H. Hayashi, and T. Takagishi, J. Control. Rel., 59, 63 (1999) https://doi.org/10.1016/S0168-3659(98)00180-1
  19. K. Kono, K. Yoshino, and T. Takagishi, J. Control. Rel., 80, 32 (2002)
  20. H. Takeuchi, H. Kjima, T. Toyoda, H. Yamamoto, T. Hino, and Y. Kawashima, Eur. J. Pharma. Biopharm., 48, 123 (1999) https://doi.org/10.1016/S0939-6411(99)00029-6
  21. H. Takeuchi, H. Kojima, H. Yamamoto, and Y. Kawashima, J. Control. Rel., 68, 195 (2000) https://doi.org/10.1016/S0168-3659(00)00260-1
  22. H. Takeuchi, H. Yamamoto, T. Toyoda, and H. Toyobuku, Int. J. Pharm., 164, 103 (1998) https://doi.org/10.1016/S0378-5173(97)00404-3
  23. J. Guo, Q. Ping, G. Jiang, L. Huang, and Y. Tong, Int. J. Pharm., 260, 167 (2003) https://doi.org/10.1016/S0378-5173(03)00254-0
  24. E. Ruel-Gariepy, G. Leclair, P. Hildgen, A. Gupta, and J. C. Leroux, J. Control. Rel., 82, 373 (2002) https://doi.org/10.1016/S0168-3659(02)00146-3
  25. R. C. Krieg, Y. Dong, K. Schwamborn, and R. Knuechel, J. Biochem. Biophys. Methods, 65, 13 (2005) https://doi.org/10.1016/j.jbbm.2005.08.005
  26. A. S. Determan, Brian G., Trewyn, Victor S. Y. Lin, and Marit Nilsen-Hamilton, Balaji Narasimhan, J. Control. Rel., 100, 97 (2004) https://doi.org/10.1016/j.jconrel.2004.08.006
  27. C. Remun an-Lopez, M. L. Lorenzo-Lamosa, J. L. Vila-Jato and M. J. Alonso, Eur. J. Pharm. Biopharma., 45, 49 (1998) https://doi.org/10.1016/S0939-6411(97)00122-7
  28. Ozlem Ogun Cirli and Vasif Hasirci, J. Control. Rel., 96, 85 (2004) https://doi.org/10.1016/j.jconrel.2004.01.008
  29. B. N. Joshi, M. N. Sainani, K. B. Bastawade, V. S. Gupta, and P. K. Ranjekar, Biochem. Biophys. Res. Commun., 246 382 (1998) https://doi.org/10.1006/bbrc.1998.8625